Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (20%) |
| No statute on record | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOAZZAMI, NAGHMEH NINA | 1 | 71.7% | +42.8% |
| KONOPKA, CATHERINE ANNE | 1 | 58.8% | +63.7% |
| MCLEOD, AFRICA MHAIRIE | 1 | 44.7% | +68.6% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 36.4% | +70.1% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 56.5% | +36.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17497725 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | DACE DENITO, ALEXANDRA GERALDINE | 45d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17830212 | GENE EDITING SYSTEMS COMPRISING A CRISPR NUCLEASE AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | 103d overdue |
| 17497725 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | DACE DENITO, ALEXANDRA GERALDINE | 45d overdue |
| 18356822 | COMPOSITIONS COMPRISING A VARIANT POLYPEPTIDE AND USES THEREOF | MOAZZAMI, NAGHMEH NINA | 19d |
| 17916270 | COMPOSITIONS COMPRISING A CAS12I2 VARIANT POLYPEPTIDE AND USES THEREOF | MCLEOD, AFRICA MHAIRIE | 33d |
| 18251183 | COMPOSITIONS COMPRISING AN RNA GUIDE TARGETING BCL11A AND USES THEREOF | KONOPKA, CATHERINE ANNE | 50d |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| 1652 | 1 |
| 1637 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18356822 | COMPOSITIONS COMPRISING A VARIANT POLYPEPTIDE AND USES THEREOF | MOAZZAMI, NAGHMEH NINA | 1652 | Other | Non-Final OA | 19d | Pending | Jul 21, 2023 |
| 18251183 | COMPOSITIONS COMPRISING AN RNA GUIDE TARGETING BCL11A AND USES THEREOF | KONOPKA, CATHERINE ANNE | 1635 | Other | Non-Final OA | 50d | Pending | Apr 28, 2023 |
| 17916270 | COMPOSITIONS COMPRISING A CAS12I2 VARIANT POLYPEPTIDE AND USES THEREOF | MCLEOD, AFRICA MHAIRIE | 1635 | Other | Final Rejection | 33d | Pending | Sep 30, 2022 |
| 17830212 | GENE EDITING SYSTEMS COMPRISING A CRISPR NUCLEASE AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | 1637 | Other | Final Rejection | 103d overdue | Pending | Jun 01, 2022 |
| 17497725 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §101 | Non-Final OA | 45d overdue | Pending | Oct 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial